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license (http://creativestudy neurodegenerative diseases, but their benefits to patients/science might be greatly enhanced
by improving standardization and cross-validation. In this EU Joint Programme-Neurodegenerative
Diseases Research–funded project, we surveyed the neuroimaging community to assess perceived
barriers in multicentric neuroimaging harmonization and actions to overcome them.
Methods: An anonymous survey addressed researchers, clinicians, pharma industry, and profes-
sional associations, inquiring about both general and modality-specific harmonization barriers.
Results: Survey participants (459) represented an international (37 countries) multidisciplinary
community. We identified two sets of funding actions, one proposing the creation of an updated
hub of documents to help researchers plan and execute multicentric neuroimaging studies capitalizing
from previous studies, and the other focused on modality-specific harmonization challenges in future
neurodegenerative diseases clinical trials.
Discussion: This large survey of priorities and actions may help define harmonization calls launched
by worldwide science funding agencies.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Early and accurate differential disease diagnosis, prog-
nosis, progression tracking, and intervention assessment
are still a challenge for the most prevalent neurodegenerative
diseases (NDs) [1–3]. There is a consensus that molecular,imer’s Association. This is an open access article under the CC BY-NC-ND
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positron emission tomography (PET) and magnetic
resonance imaging (MRI) may greatly help these clinical
challenges by means of an improved standardization and
cross-validation [4–11]. These developments would allow
large-scale neuroimaging studies with higher statistical po-
wer to characterize ND. Although considerable progress
has been made on the harmonized use of multicentric neuro-
imaging biomarkers, several challenges remain. Additional
promising techniques (e.g., electroencephalography
[EEG]; single photon emission computerized tomography
[SPECT]) pose similar issues.
In this study (http://www.sra-ned.org/), we assess the cur-
rent state of neuroimaging biomarker harmonization needs
of MRI, PET, SPECT, and EEG in the context of large-
scale multicenter neurodegenerative studies. To accomplish
this goal, we surveyed the expert international community to
identify (1) current barriers for a harmonized use of MRI/
PET-SPECT/EEG biomarkers obtained from multicenter
studies in NDs and (2) community-driven solutions to over-
come these barriers.Table 1
Summary of general high-level neuroimaging harmonization perceived
barriers reported by the survey and actions proposed to address them
General high-level barriers Actions to address barriers
 Insufficient information to
participate in multicentric neu-
roimaging consortia
 Create an open-access web-based
forum platform with updated
information
 Insufficient funding or lack of
access to expertise for neuroi-
maging harmonization
 Create a standardized registry to
help plan and budget multicentric
studies
 Difficulty in harmonizing rec-
ommendations for neuroimaging
harmonization procedures
 Create an updated registry of
neuroimaging harmonization
findings
 Lack of multidisciplinary educa-
tion transversal to neuroimaging
acquisition protocols, analysis to
derive markers, clinical needs to
validate markers
 Continue to invest in multidisci-
plinary education in the context
of neuroimaging biomarkers2. Methods
2.1. Survey concept and structure
A survey was created aimed at understanding neuroimag-
ing community thoughts on the most pressing barriers that
currently hinder the harmonization of procedures and extrac-
tion of biomarkers derived from neuroimaging data (MRI,
PET/SPECT, and EEG) collected in multicenter studies car-
ried out in patients with neurodegenerative disorders. Three
working groups were formed per imaging modality, each
one lead by two people to cover clinical and methodological
expertise in each modality (http://www.sra-ned.org/). In
addition, an Advisory Reference Group oversaw the work.
The survey was structured in three parts: Part I: Back-
ground information about survey participants, who were
asked to choose one neuroimaging modality from MRI,
PET-SPECT, and EEG with dominant expertise. Part II:
This section was specific to each neuroimaging modality
while covering the following three general questions in the
context of NDs: Are there high-level barriers to participate
in multicenter neuroimaging ND studies in the chosen mo-
dality? What modality-specific biomarkers should be
harmonized? How should these modality-specific bio-
markers be harmonized? Part III: Final remarks, the same
for all modalities, and aimed to collect comments about rele-
vant issues not addressed by the survey.
2.2. Survey implementation and dissemination
The survey was implemented inMonkey Survey platform
(https://it.surveymonkey.com). Participants were anony-
mous to encourage participation while allowing them to
identify themselves. Dissemination of the survey was via
e-mail to clinicians and researchers with a clinical (e.g.,neurologist, neuroradiologist, nuclear medicine specialists,
and so forth) and/or methodological (e.g., engineer, physi-
cist, and so forth) background with experience in multicenter
neuroimaging ND projects. Dissemination via e-mail was
also made to relevant scientific field societies such as
research/clinical associations, professional groups, and
points of contact in the pharmaceutical and neuroimaging in-
dustry. Several associations accepted to disseminate the sur-
vey while not giving us the e-mail lists. This prevented an
overall quantification of how many people received the sur-
vey invitation.
The complete survey with the list of associations con-




The surveywas completed by 459 participants of theMRI/
PET-SPECT/EEG community between February 1 and
March 31, 2017 (MRI 53.6% of participants, EEG 30.3%,
and PET-SPECT 16.1%). The participants were representa-
tive of a strong multidisciplinary community, dominated by
research and academia whereas industry and participants
from clinical settings were also included. Participants repre-
sented also an international community (Europe 75%; North,
Central, South America 20%; Asia, Oceania, Africa 5%).
Here, we outline the main findings of the survey, the com-
plete set of results can be found in the full SRA-NED Project
Report (http://www.neurodegenerationresearch.eu/wp-content/
uploads/2019/01/JPND-Brain-Imaging-Working-Group-Report_
SRA-NED_FullReport.pdf). The survey provided information
of perceived barriers that led to two broad classes of action
recommendations, one that is independent of neuroimaging
modality (outlined in Table 1), and then recommendations
that are specific to each one of the three imaging modalities
(outlined in Table 2).
Table 2
Summary of methodological barriers for the harmonization of multicentric neuroimaging protocols in the context of ND reported in the survey and actions
proposed to address them
Neuroimaging
modality Perceived barriers Actions to address barriers
MRI  Unclear recommendations for acquisition and analyses details for
multivendor protocols using state-of-the-art equipment
 Unclear quality control guidelines and reference values in the
context of different markers
 Unclear recommendations for retrospective harmonization of
existing data acquired with different protocols
 Harmonize multivendor state-of-the-art acquisition and quality
assurance. In particular three-dimensional anatomic and
quantitative tissue mapping (e.g., susceptibility, tissue relaxation,
myelin, and so forth), advanced structural (diffusion), and
functional (resting state) connectivity
 Quantify reproducibility for different markers
 Standardize quality assurance for different markers. Evaluate
optimal markers for different ND types, stages, and experimental
designs (cross-sectional or longitudinal)
 Standardization of retrospective MRI data harmonization strate-
gies
PET-SPECT  Lack of harmonization for analysis tools and quantification (FDG-
PET, amyloid PET, tau PET, and dopaminergic PET/SPECT)
 Lack of standardization across amyloid PET tracers
 Lack of public normative reference data, especially healthy vol-
unteers
 Lack of PET-SPECT comparisons (dopaminergic tracers)
 Harmonize multivendor image reconstruction parameters and
quantification
 Develop public databases of normal and ND patients (uniform
with respect to acquisition and quantification)
 Create centralized analysis platforms for widely available
markers lacking standardization of analysis such as FDG and
dopaminergic markers
EEG  Lack of standardization of spectral source EEG analysis and high-
resolution recordings
 Lack of quality assurance standardization (ocular motion and
cardiac artifacts)
 Lack of clarity of the limits and opportunities of EEG biomarkers
for NDs
 Harmonize multivendor state-of-the-art acquisition and quality
assurance EEG protocols
 Harmonize biomarker extraction using spectral or time-domain
analysis: resting state (eyes open/closed) and event related
(oddball, and so forth)
 Quantify test-retest reliability from multivendor EEG data
 Evaluate best biomarkers for different NDs and experimental
designs (cross-sectional, longitudinal)
Abbreviations: EEG, electroencephalography; MRI, magnetic resonance imaging; ND, neurodegenerative diseases; PET, positron emission tomography;
SPECT, single-photon emission computed tomography.
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the following main barriers, which were common across
the three neuroimaging modalities evaluated (Table 1): (1)
lack of updated information and resources to effectively
participate in multicenter ND studies (77% MRI, 61%
EEG, and 75% PET-SPECT groups); (2) lack of guidelines
for the harmonization of data acquisition using state-of-
the-art equipment and protocols, biomarker extraction, and
statistical modeling; (3) a general tendency of cost underes-
timation, in particular for software resources as well as for
human resources with the relevant expertise, such as for
the implementation of multicentric acquisition protocols
and data analyses; (4) lack of harmonized recommendations
resulting from multiple multicentric harmonization efforts.
To address these general barriers, we recommend that the
EU Joint Programme-Neurodegenerative Diseases Research
(JPND) agenda includes the following action (Table 1):
establish an EU neuroimaging harmonization Working
Group, considering MRI/PET-SPECT/EEG neuroimaging
modalities, with advisors beyond EU, with commitments
that include the following:
1. Develop and maintain an open-access web-based
forum that can serve as updated centralized repository
of information relevant to multicenter studies in NDs,
generated by this group and from other initiatives.
This resource should also enable a platform wherepeople can exchange information and discuss new
literature findings and recommendations.
2. Develop and maintain updated consensus guidelines
on the harmonization of neuroimaging MRI/PET-
SPECT/EEG data acquisition and analysis in multi-
center studies in NDs. Where applicable, these guide-
lines should relate acquisition strategies with different
target-derived markers in the context of studying
different NDs using different experimental designs
(cross-sectional vs. longitudinal studies, observational
vs. treatment effect studies, and so forth).
3. Develop and maintain standardized registry for plan-
ning and budgeting multicenter neuroimaging pro-
jects. This registry should include the comprehensive
list of recommendations of aspects that are agreed to
be typically essential parts of any successful multi-
center study. Such guidelines could be helpful to
both researchers preparing grant applications and
funding agencies when reviewing project proposals.
4. Develop and maintain an updated registry of neuroi-
maging harmonization efforts for NDs that outlines
key differences and common aspects of past/ongoing
projects. Promote constructive synergies that help
cross-reference recommendations and information
from relevant multicentric neuroimaging biomarker
harmonization projects in NDs.
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nars/workshops/courses on topics relevant to the
harmonized use of neuroimaging biomarkers in
NDs. This activity could be synchronized with peri-
odic national and international conference meetings
to offer relevant satellite events.
With specific regards to MRI modality (Table 2), the sur-
vey reflected consensus on the need to harmonize multiven-
dor state-of-the-art acquisition protocols (given the wider
availability modern systems with strong image acceleration
options) for high-spatial resolution anatomic MRI
(including quantitative tissue mapping), prospective head
motion correction tools, microstructure and connectivity
characterizations from diffusion MRI, as well as high-
temporal resolution functional and perfusion MRI neuroi-
maging. There is a particular need for characterizing
test-retest reproducibility errors given the interest in longitu-
dinal studies. In addition, there is a need to develop auto-
mated quantitative quality assurance methods specific for
the various methodologies in the context of multicenter
studies. There is also a need to develop methods that are
able to harmonize existing data already acquired without
standardized protocols, to make the most out of existing
data and past investments.
With specific regards to PET-SPECT modalities
(Table 2), the JPND agenda may fund the harmonization
of image reconstruction parameters across PET and SPECT
vendors as a first necessary step. The action may consider
also creating public databases of normal and ND patients
as well as creating centralized analysis platforms.
With specific regards to the EEG modality (Table 2), the
JPND agenda may fund the harmonization of the recordings
parameters and spectral or time-domain analyses of resting
state eyes-closed and eyes-open EEG and event-related po-
tentials (especially oddball paradigms), as well as the defini-
tion of the best EEG biomarkers for each data analysis
technique and experimental/clinical condition.4. Discussion
This survey supports the need for two types of funding ac-
tions. One type of action is general, aimed at creating an up-
dated hub of information/updated documentation that can
help researchers plan and execute multicentric neuroimag-
ing studies capitalizing efficiently on lessons learned from
previous relevant investments, particularly in neuroimaging
modules of clinical trials in NDs. The other type of funding
action is neuroimaging modality specific and may be
composed of multiple actions focused to address the key
challenges for the different modalities.
The actions here proposed are consistent with current EU
legislation developments aimed at allowing secondary use of
health data. Such legislation would also lend itself to the sec-
ondary use of multicenter neuroimaging data once these datahave been obtained within a commonmethodological frame-
work. This therefore suggests that funding for the hereby
proposed actions would come timely given the political
agenda of health research legislation in the EU.
In conclusion, this JPND initiative produced the largest
survey on the barriers and tentative solutions for the harmo-
nized use of neuroimaging MRI/PET-SPECT/EEG tech-
niques for multicentric clinical studies in NDs. The
Working Group of this initiative transposed those solutions
in a tentative agenda for JPND to overcome those barriers.
This agenda is also consistent with current EU legislation de-
velopments relevant to the use of health data.
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1. Systematic review: Early and accurate differential
diagnosis, progression tracking and intervention
assessment are currently challenging for neurode-
generative diseases (ND). Although molecular, func-
tional and structural neuroimaging biomarkers are
largely used, there is still a need for multicentric
harmonization and modality cross-validation of
acquisition and analysis strategies.
2. Interpretation: Our survey helped identify and prior-
itize perceived barriers for the harmonization of neu-
roimaging biomarkers in multicentric ND studies.
The evaluation of the barriers allowed us to propose
two set of actions to overcome them: one action pro-
poses the creation of an updated hub of information/
documents to help researchers plan and execute mul-
ticentric neuroimaging studies capitalizing from
previous studies, and the other action focuses on mo-
dality-specific harmonization challenges in future
ND clinical trials.
3. Future directions: The priorities and proposed ac-
tions resulting from this survey may be considered
by worldwide funding agencies interested the
improvement of standardization and cross-validation
of neuroimaging ND biomarkers. Such initiatives
may contribute to ND clinical trials.
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